Vertex drops mRNA cystic fibrosis program over 'tolerability' issues
Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy after facing challenges similar to those that have troubled other parts of the field in delivering the genetic medicine. The Boston-based company ...
Original Source
Read the full article at Endpoints →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.